Bacteria Or Actinomycetales Patents (Class 435/7.32)
-
Publication number: 20140080119Abstract: A molecular net formed as a branched pseudorandom copolymer including two broad classes of subunits: capture agents and linking agents. The subunits self-assemble to form a structure capable of binding to predetermined targets. The binding can then be detected.Type: ApplicationFiled: July 9, 2013Publication date: March 20, 2014Inventors: Emily A. STEIN, Michael A. EVANS
-
Publication number: 20140079727Abstract: The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO:1. The present invention further relates to the nucleic acid molecules comprising a nucleotide sequence coding for the polypeptide, vectors comprising the nucleic acid molecules, and host cells for the expression of the polypeptides. In addition, the present invention relates to the use of the polypeptide as a human medical, veterinary medical or diagnostic substance, as an antimicrobial substance in food, in cosmetics, as disinfecting agent or in the environmental field.Type: ApplicationFiled: July 24, 2009Publication date: March 20, 2014Inventors: Martin Loessner, Mathias Schmelcher
-
Patent number: 8663909Abstract: This invention describes a device consisting of a micro channel plate, filter, and porous holder for filter, which is substituted by a pure agar block during method performance, and supportive structural elements. The device is intended for rapid detection and/or identification of microorganisms. Microorganisms are trapped by filtration in long (diameter/length=1/10-1/100), cylindrical, parallel, micro-channels that are open from both sides and attached to a filter from one side. A micro channel plate houses a multiplicity of micro channels (possible diameter of each channel=1-30 ?m, length 100-1000 ?m, and number on centimeter2=100,000-1,000,000). The micro channel plate with cells trapped on the surface of the filter is attached to an agar block impregnated by artificial substrate(s) so that the molecules of the artificial substrates will fill all micro channels. Trapped cells produce colored or fluorescent molecules from artificial substrates.Type: GrantFiled: April 20, 2005Date of Patent: March 4, 2014Assignee: Nanologix, Inc.Inventor: Sergey Gazenko
-
Patent number: 8663911Abstract: Methods, assays, and apparatus are disclosed for testing of antigens associated with intestinal and/or blood-brain barrier permeability. For example, blood, saliva or other bodily fluid can be tested for binding (1) to a bacterial toxin (preferably a lipopolysaccharide), and (2) binding to tissue antigens selected from at least one of (a) a gut-related antigen and (b) a blood brain barrier-related antigen. Analysis of test results can be used to assist in detecting and diagnosing diseases associated with leaky gut syndrome (whether due to paracellular or transcellular pathways, and whether due to bacterial toxins or some other cause) and/or to diseases associated with excessive blood brain barrier permeability, which are contemplated herein to include both neuroinflammation and/or neuroautoimmunity conditions, and especially amyotrophic lateral sclerosis, Parkinsons disease, multiple sclerosis, Alzheimer's, or peripheral neuropathy, and major depression.Type: GrantFiled: January 26, 2012Date of Patent: March 4, 2014Assignees: Cyrex Laboratories, LLC, Immunosciences Lab, Inc.Inventor: Aristo Vojdani
-
Patent number: 8663940Abstract: The present disclosure provides methods for assessing bactericidal antibodies in a biological sample by use of human fresh whole blood from a non-immune human as a reaction medium for the assay.Type: GrantFiled: December 10, 2009Date of Patent: March 4, 2014Assignee: Children's Hospital & Research Center OaklandInventors: Dan M. Granoff, Jo Anne Welsch, Joyce Plested
-
Patent number: 8658387Abstract: Ehrlichia canis antigens that can be used to differentiate E. canis infected animals from animals that have been challenged with E. canis, e.g., vaccinated against E. canis, are disclosed. The invention also provides compositions and methods for determining the presence of E. canis antigens and antibodies.Type: GrantFiled: November 30, 2010Date of Patent: February 25, 2014Assignee: IDEXX Laboratories, Inc.Inventors: Eugene Regis Krah, III, Melissa Beall
-
Patent number: 8658386Abstract: Hybridoma cell lines which produce and secrete monoclonal antibodies which selectively bind to Mycobacterium avium subspecies paratuberculosis have been produced. Cells of M. avium subspecies paratuberculosis in biological samples may be detected and quantified by contacting the sample with the antibodies to form a M. avium subspecies paratuberculosis/antibody immunocomplex when M. avium subspecies paratuberculosis is present, which immunocomplex may then be detected. The monoclonal antibodies also may be incorporated into kits for the detection and quantification of M. avium subspecies paratuberculosis.Type: GrantFiled: November 22, 2010Date of Patent: February 25, 2014Assignee: The United States of America, as represented by the Secretary of AgricultureInventor: John P. Bannantine
-
Patent number: 8652792Abstract: The invention relates to mutant strains of the genus Sphingomonas which have a mutation in at least one gene encoding a protein involved in polyhydroxybutyrate (“PHB”) synthesis that allows the mutant strains to produce PHB-deficient Sphingans. The invention is also directed to a process for preparing a clarified Sphingan solution comprising heating aqueous Sphingan solution, in particular PUB-deficient Sphingan solution, to a clarification temperature of about 30° C. to about 70° C., and treating the solution with a clarification agent and enzymes. In addition, the invention is directed to a food or industrial product comprising a PHB-deficient and/or clarified Sphingan. One particular embodiment of the invention is directed to a clarified, PHB-deficient high-acyl gellan and the processes of making thereof.Type: GrantFiled: November 1, 2010Date of Patent: February 18, 2014Assignee: C.P. Kelco U.S., Inc.Inventors: Stan Bower, Ellen Burke, Nancy E. Harding, Yamini N. Patel, J. Carrie Schneider, Dagmar Meissner, Neil A. Morrison, Ralph Bezanson
-
Publication number: 20140037696Abstract: The present invention provides synthetic cell platforms. The synthetic cell platforms can be used for culturing cells in vitro. The synthetic cell platforms can also be implanted together with bound cells into an individual. The present invention provides methods of using the platforms to provide cells or progeny of such cells for use in various applications, including clinical applications; and methods of use of the platforms to introduce cells into an individual.Type: ApplicationFiled: April 26, 2013Publication date: February 6, 2014Applicant: The Regents of the University of CaliforniaInventors: David V. Schaffer, Kevin Edward Healy, Lauren Little, Patrick Sean Daugherty
-
Publication number: 20140011217Abstract: A portable magnetic resonance system includes a permanent magnet, a nuclear magnetic resonance probe, and control electronics. The control electronics are configured to transmit to the probe a magnetic resonance excitation signal having an excitation frequency f, receive from the probe a magnetic resonance measurement signal, detect in the magnetic resonance measurement signal a magnetic resonance frequency f0, and automatically adjust the excitation frequency f until the difference between the excitation frequency and the magnetic resonance frequency is approximately equal to a target offset.Type: ApplicationFiled: March 21, 2012Publication date: January 9, 2014Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Ralph Weissleder, Hakho Lee, David Issadore
-
Publication number: 20140011216Abstract: The present invention is related with the field of Biomedicine. It comprises the engineering of the Pertactin protein (Prn) and using it as part of bacterial vaccines, and more precisely, as part of acellular vaccines against Bordetella pertusis. The engineered Prn molecules comprise on their structure polimorfisms from different B. pertussis strains, and induce immune responses with protective capacity and opsonophagocytic activity when assayed as vaccines, higher than that generated by other pre-existing vaccines. The engineered Prn variants of the present invention are applicable in human and veterinary medicine.Type: ApplicationFiled: August 14, 2013Publication date: January 9, 2014Inventors: Diogenes Quintana Vazquez, Tamara Menendez Medina, Anabel Alvarez Acosta, Yoelys Cruz Leal, Gerardo Enrique Guillen Nieto
-
Patent number: 8623383Abstract: The invention relates to the construction of recombinant, immunodominant polypeptides against spotted fever group Rickettsia. The invention also relates to a method for the use of the recombinant proteins, either singly or in combination, in detection and diagnostic assays of spotted fever. The proteins can also be used to induce immune response against spotted fever group Rickettsia.Type: GrantFiled: June 8, 2009Date of Patent: January 7, 2014Assignee: The United States of America as represented by the Secretary of the NavyInventor: Wei-Mei Ching
-
Publication number: 20130344477Abstract: A bindable target such as a bacterial cell, virus, or molecule is captured from a liquid by contacting the liquid with magnetically attractable particles have an affinity for the target, and causing said particles to move repeatedly through said liquid to at least one solid support zone by attractive magnetic forces to capture the target onto said particles. The particles may be ferromagnetic, paramagnetic or superparamagnetic particles and may bear antibody, antibody binding fragments, a substance having an epitope capable of reacting in a specific manner with an antibody, an aptamer, a nucleic acid sequence or a nucleic acid analogue sequence, biotin, avidin or streptavidin.Type: ApplicationFiled: January 6, 2012Publication date: December 26, 2013Applicant: MATRIX MICROSCIENCE LIMITEDInventor: Adrian Parton
-
Publication number: 20130337437Abstract: A process for detecting cells from a sample, comprising the following steps: (a) applying the sample or a fraction of the sample in liquid phase in a direction of flow to a porous, generally two-dimensional support with pores having on the surface thereof at least one binding molecule specific for the cells to be detected or for fragments of such cells; (b) allowing the cells to be detected or of fragments of such cells to enter from the sample or sample fraction into the pores of said porous, generally two-dimensional support, said pores having such a mean pore size that the cells or fragments to be detected are able to enter into the pores; (c) retaining the cells or fragments to be detected by at least one binding molecule specific for the cells or fragments to be detected; (d) performing an optical read-out method on said substantially two-dimensional support by an imaging method, optionally after the cells or cell fragments to be detected have been labeled with a labeling agent; wherein (e) the opticaType: ApplicationFiled: February 10, 2012Publication date: December 19, 2013Applicant: fzmb GmbH Forschungszentrum Fuer Medizintechnik Und BiotechnologieInventors: Stephan Henze, Peter Miethe
-
Publication number: 20130337436Abstract: The present disclosure relates to a substrate having a surface comprising nanoparticles or groups of nanoparticles which the linear optical response does not depend on the polarisation of the incident field of a Gaussian beam having an axis of propagation that is directed perpendicularly to the surface of the substrate. The shape or arrangement of the groups of nanoparticles has a Cn-type axis of symmetry perpendicular to the surface, where n is a number equal to three or greater than four, and the shape of the nanoparticles has a Cn-type axis of symmetry perpendicular to the surface, where n is a number no less than three, to allow strong enhancement of the beam close to the surface. The disclosure relates to use of substrates for detection and/or measurement of chemical, biochemical or biological molecules, wherein the molecules can be present in trace amounts in a liquid or other medium.Type: ApplicationFiled: September 7, 2011Publication date: December 19, 2013Applicant: UNIVERSITE DE TECHNOLOGIE DE TROYESInventors: Timothee Toury, Marc Lamy De La Chapelle, Hong Shen
-
Patent number: 8609355Abstract: Methods, devices, and kits are provided herein for the accurate and rapid detection of disease causing microbes in a sample by the detection of microbial components of which correlate to the presence of the microbe. Kits include a first binding agent operatively coupled to an immobilized support; and a second binding agent operatively coupled to one or more pH indicating moieties wherein the first and second binding agents bind with sufficient specificity to the microbial component to permit detection of that component which correlates to the presence of the microbe in the sample.Type: GrantFiled: July 25, 2012Date of Patent: December 17, 2013Assignee: Indicator Systems International, Inc.Inventors: Gerald F. Swiss, Laurie B. F. Stellman
-
Patent number: 8609350Abstract: The invention provides methods and compositions for the detection and treatment of Anaplasma phagocytophilum and Anaplasma platys infection.Type: GrantFiled: April 17, 2012Date of Patent: December 17, 2013Assignee: IDEXX Laboratories, Inc.Inventors: Jiayou Liu, Ramaswamy Chandrashekar
-
Patent number: 8597897Abstract: The present invention relates to a method of rapidly detecting microorganisms using nanoparticles, and more particularly to a method and device of rapidly detecting microorganisms by adding, to the microorganisms to be detected, nanoparticles having immobilized thereon an antibody that binds specifically to the microorganisms to be detected, subjecting the mixture to an immune reaction to form a reaction solution, passing the reaction solution through a microorganism-concentrating film to concentrate the microorganisms, capturing microorganisms, which was immune-reacted with the antibody-immobilized nanoparticles, by a microorganism-capturing filtration membrane, and determining the presence and concentration of the microorganisms.Type: GrantFiled: November 24, 2010Date of Patent: December 3, 2013Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Min Gon Kim, Yong Beom Shin, Yoon Joo Sung
-
Publication number: 20130316333Abstract: The present invention relates to a method for detecting at least one microorganism in a sample, including: cultivating the sample in a liquid medium in the presence of at least one specific ligand of the microorganism, and at least one scavenger having a lower affinity to the microorganism than the ligand, the binding of a compound to the ligand producing a first measurable signal and the binding of a compound to the scavenger producing a second measurable signal; determining the values of the first and second signals for at least one cultivation period; wherein it is deduced that the sample includes the microorganism when the values of the first signal and second signal are different for the same cultivation period.Type: ApplicationFiled: November 30, 2011Publication date: November 28, 2013Applicant: Commissariat A L'Energie Atomique Et Aux Energies AlternativesInventors: Yoann Roupioz, Roberto Calemczuk, Thierry Vernet, Thierry Livache, Sihem Bouguelia, Claire Durmort
-
Publication number: 20130309237Abstract: Described herein are antigen binding proteins that bind to pathogenic mycobacteria-derived Mannose-Capped Lipoarabinomannan (ManLAM) and methods and kits for using and making the antigen binding proteins. Also described herein are antigen binding proteins that bind to the alpha 1-2 linkage mannose caps of ManLAM, antigen binding proteins that bind to a mannose cap with up to three alpha 1-2 linked mannose residues, and antigen binding proteins that bind to LAM with a mannose sugar capping motif.Type: ApplicationFiled: January 25, 2012Publication date: November 21, 2013Applicants: DSO NATIONAL LABORATORIES, NATIONAL UNIVERSITY OF SINGAPOREInventors: Paul Anthony Macary, Conrad En Zuo Chan, Brendon John Hanson, Markus R. Wenk
-
Publication number: 20130302813Abstract: Accurate and rapid differentiation of the outbreak strain ribotype 027 from other possible Clostridium difficile (C. difficile) strains, using stool samples, facilitates decision making for treatment options. Cell wall protein V (CwpV) contains a cell wall binding domain conserved among C. difficile strains and a variable domain which is antigenically different among C. difficile strains. In embodiments, antibodies against the 027-specific region in CwpV are used in diagnostic tests to detect ribotype 027 in culture or fecal samples.Type: ApplicationFiled: May 8, 2013Publication date: November 14, 2013Applicant: TECHLAB, INC.Inventors: MANLI Y. DAVIS, KRISTA A. WILLIAMS, JOCELYN N. BROWNING, DAVID M. LYERLY
-
Publication number: 20130302788Abstract: A device for detecting at least one analyte (and in some embodiments two, three, or four or more different analytes) in a liquid sample generally comprises (i) a support having a chamber for receiving a biological fluid therein, wherein said chamber is an elongate chamber having a length axis; (ii) a carrier or agitator in said elongate chamber, said carrier or agitator having opposite end portions and a side portion, the carrier or agitator dimensioned to travel in said chamber along said length axis and/or permit said liquid sample to flow in the chamber therearound, either (or both) thereby agitating the liquid sample; and (iii) at least one anti-analyte antibody coupled to either the carrier and/or the chamber side wall.Type: ApplicationFiled: May 8, 2013Publication date: November 14, 2013Applicant: Advanced Animal Diagnostics, Inc.Inventors: Rodolfo R. Rodriguez, David A. Calderwood
-
Patent number: 8580522Abstract: Methods for aiding in the diagnosis of disorders including, but not limited to, PDDs (Pervasive Development Disorders), Dysautonomic disorders, Parkinson's disease and SIDS (Sudden Infant Death Syndrome). In one aspect, a diagnosis method comprises analyzing a stool sample of an individual for the presence of a biological marker (or marker compound) comprising one or more pathogens, which provides an indication of whether the individual has, or can develop, a disorder including, but not limited to, a PDD, Dysautonomia, Parkinsons disease and SIDS. Preferably, the presence of one or more pathogens is determined using a stool immunoassay to determine the presence of antigens in a stool sample, wherein such antigens are associated with one or more pathogens including, but not limited to, Giardia, Cryptosporidium, E. histolytica, C. difficile, Adenovirus, Rotavirus or H. pylori.Type: GrantFiled: August 12, 2011Date of Patent: November 12, 2013Assignee: Curemark, LLCInventor: Joan M. Fallon
-
Publication number: 20130295070Abstract: The present invention relates to a modified polypeptide with a biological activity to lyse cell walls of bacteria, wherein the polypeptide has no caspase, clostripain, enterokinase, factor Xa, granzyme B, staphylococcus peptidase I (V8 Protease), plasmin, streptopain, bacillolysin and/or thrombin cleavage site. The invention further relates to nucleic acids with a sequence encoding a polypeptide according to the present invention.Type: ApplicationFiled: July 18, 2013Publication date: November 7, 2013Inventors: Holger GRALLERT, Michael FORCHHEIM
-
Patent number: 8568989Abstract: The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to Borrelia antigens. The peptide compositions comprise polypeptide sequences comprising variants in the IR6 domain of the Borrelia VlsE protein. The invention also provides devices, methods, and kits comprising such peptide compositions and useful for the detection of antibodies that bind to Borrelia antigens and the diagnosis of Lyme disease.Type: GrantFiled: November 17, 2010Date of Patent: October 29, 2013Assignee: Abaxis, Inc.Inventors: Rajesh K. Mehra, Kenneth P. Aron, Dennis M. Bleile
-
Publication number: 20130281503Abstract: The present disclosure provides methods and compositions useful for screening agents for activity in modulating response regulator signaling activity, which is, in turn, useful for determining whether these agents modulate biofilm formation or lowers the minimum inhibitory concentration (MIC) of an antibiotic, useful in determining or selecting optimum agents and/or agent dosages in modulating a biofilm of interest or lowering the minimum inhibitory concentration (MIC) of an antibiotic, and useful as a research tool for studying response regulators.Type: ApplicationFiled: April 26, 2013Publication date: October 24, 2013Applicant: North Carolina State UniversityInventor: North Carolina State University
-
Publication number: 20130280699Abstract: An assay device (1) for determining the presence and/or amount of an analyte present or potentially present in a liquid sample comprises: (i) a capillary tube (2) having an upstream region (3) into which the sample to be assayed is introduced for transfer by capillary action along the capillary tube to a downstream region thereof; (ii) a collection of first binding partners (5) immobilised within the capillary tube (2), said first binding partners (5) being capable of specifically binding to the analyte; (iii) a collection of second binding partners (6) displaceabley bound to a fraction of said first binding partners (5) whereby there are free first binding partners (5) immobilised within the capillary tube, said second binding partners (6) having a label and being displaceable from the first binding partners (5) by the analyte to be detected; and (iv) a detection region (4) for sample that has transferred to said downstream region of said capillary tube, said detection region being adapted to generate a deteType: ApplicationFiled: October 17, 2011Publication date: October 24, 2013Applicant: Moorlodge Biotech Ventures LimitedInventors: Stephen John Minter, Georgios Patsos
-
Patent number: 8563251Abstract: The invention provides compositions (e.g., kits) and methods for determine the number of bacteria and other microbes in samples having low concentrations of microbes, for use, e.g., in biological warfare defense, microbe detection and agricultural and environmental sciences.Type: GrantFiled: May 11, 2007Date of Patent: October 22, 2013Assignee: San Diego State University (SDSU) FoundationInventors: Forest Rohwer, Linda Wegley
-
Publication number: 20130273572Abstract: A method for diagnosing Lyme disease status in a mammal is provided. The method entails, in a biological sample obtained or derived from a mammal, determining antibodies to Borrelia burgdorferi (B. burgdorferi) outer surface proteins (Osp) OspA, OspC, and OspF. Based upon determining the OspA, OspC, and OspF antibodies, the mammal can be diagnosed as vaccinated, not vaccinated, infected or not infected with B. burgdorferi. Mammals that have early, intermediate or chronic B. burgdorferi infection can also be identified. The method is particularly suited for use with horses and dogs. Isolated or recombinant B. burgdorferi antigens and compositions that contain them are also provided.Type: ApplicationFiled: September 27, 2011Publication date: October 17, 2013Applicant: CORNELL UNIVERSITYInventor: Bettina Wagner
-
Publication number: 20130266606Abstract: A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian Borrelia infections.Type: ApplicationFiled: October 19, 2011Publication date: October 10, 2013Applicant: VIRGINIA COMMONWEALTH UNIVERSITYInventors: Richard T. Marconi, Christopher Earnhart
-
Patent number: 8551407Abstract: A sensor comprising a membrane containing bacteriorhodopsin. In one embodiment, the sensor comprises a layer of purple membrane between a first and a second electrode, wherein the electrodes are connected to a circuit such that a signal is produced when a charge is transferred across the membrane. In another embodiment, the sensor comprises a field effect transistor with a layer of purple membrane deposited on the gate. The layer of purple membrane may be further functionalized by adding fluorophores to the layer of purple membrane. The fluorophores may be deposited adjacent to the layer of purple membrane, or the fluorophores may be attached to the layer of purple membrane with linkages. The fluorophores or linkages between the fluorophores and the purple membrane may be functionalized with receptors to produce sensors for targeted chemical or biological species.Type: GrantFiled: December 1, 2008Date of Patent: October 8, 2013Assignee: Michigan Technological UniversityInventors: Craig Friedrich, Donald Lueking, Mark Griep
-
Patent number: 8546093Abstract: The present invention relates to an antibody against a protein specifically expressed in methicillin-resistant strains of Staphylococcus aureus (MRSA), and a method and a kit for detecting MRSA. The present invention enables a fast and accurate detection of MRSA by using both a PBP2a-specific antibody for the detection of PBP2a and a Protein A-specific antibody for the detection of Protein A.Type: GrantFiled: June 24, 2009Date of Patent: October 1, 2013Assignee: Dinona Inc.Inventors: Hyung-Geun Song, Sang-Soon Yoon, Hae-Jung Kim, Gil-Yong Jee, Mi-Hyang Shin, Yu-Ri Moon
-
Patent number: 8546071Abstract: A cell-lysate extract based assay reagent for detecting quorum sensing signals is generally provided, along with methods of making and using the same. The assay reagent generally includes a cell-lysate extract formed from a biosensor bacterium (e.g., Agrobacterium tumefaciens NTL4 (pCF218)(pCF372)) and a detecting substrate (e.g., an absorbance-based or luminescence-based substrate). The cell-lysate extract can be prepared by (1) disrupting the cell membranes of the biosensor bacterium to release the cellular components into a solution, (2) centrifuging the resulting solution, and (3) removing the resulting supernatant solution.Type: GrantFiled: July 28, 2008Date of Patent: October 1, 2013Assignee: University of South CarolinaInventors: Alan W. Decho, Tomohiro Kawaguchi, Yung-pin Chen
-
Publication number: 20130251748Abstract: The present invention relates a method for vaccinating a mammal to produce an antibody against Enterobacteriaceae infection caused by Klebsiella pneumoniae, Salmonella typhi, or E. coli in central nervous system and/or peripheral blood circulation, which comprises administering an effective amount of an OmpK36/homologues or its derivatives to the mammal.Type: ApplicationFiled: July 10, 2012Publication date: September 26, 2013Applicant: NATIONAL DEFENSE MEDICAL CENTERInventors: Leung-Kei Siu, Feng-Yee Chang, Yung-Chung Lin, Chang-Phone Fung, Yip-Mei Liu, Jiun-Han Chen, Yu-Kuo Tsai, Pele Choi-Sing Chong, Chih-Hsiang Leng, Shih-Jen Liu, Hsin-Wei Chen
-
Patent number: 8541242Abstract: The present invention provides assays and devices for detection of substances in liquid samples. The assays and devices utilize passive diffusion between a porous material and a porous membrane containing a specific binding pair member to enable detection of the substance of interest.Type: GrantFiled: June 29, 2011Date of Patent: September 24, 2013Assignee: Techlab, Inc.Inventors: James H. Boone, David M. Lyerly, Tracy D. Wilkins
-
Patent number: 8541227Abstract: The inventions relates to compositions and method for determining the absolute counts of cells per unit volume of a sample. Such a method comprises: (a) providing a container containing (i) a predetermined quantity of microparticles; and (ii) a cell-binding agent; in which the microparticles are disposed in or on a matrix which adheres to at least one wall of the container such that substantially all the microparticles are thereby attached to the container; (b) adding a known volume of sample to the container; (c) determining the ratio of microparticles to cells by counting microparticles and cells in a volume of the sample; and (d) determining the absolute count of cells by multiplying the number of cells per microparticle by the concentration of microparticles in the sample.Type: GrantFiled: February 6, 2006Date of Patent: September 24, 2013Assignee: Dako Denmark A/SInventors: Nanna K Christensen, Jesper Laursen, Lars Winther
-
Publication number: 20130244899Abstract: Provided is a method of detecting infection in a wound caused by an infecting organism at a wound site. Also provided is a system for detecting an infection in a wound at a wound site. Additionally, a porous pad comprising luciferase is provided.Type: ApplicationFiled: May 8, 2013Publication date: September 19, 2013Applicant: KCI Licensing, Inc.Inventors: Amy K. McNulty, Deepak V. Kilpadi, George Hutchinson, Nancy Price
-
Publication number: 20130236915Abstract: The invention provides a method of inspecting bacteria by using an outer membrane vesicle of the bacteria, which is useful for easily diagnosing a periodontopathic bacteria with high precision. An outer membrane vesicle of bacteria to be detected is previously arranged in a measuring portion of a measuring appliance, a specimen material collected from a test subject is brought into contact with the measuring portion, and an anti-outer membrane vesicle antibody corresponding to the outer membrane vesicle in the specimen material is detected on the basis of an antigen antibody reaction. A measuring appliance for executing the inspecting method of the bacteria is structured such that the outer membrane vesicle of the bacteria to be detected is previously arranged in the measuring portion.Type: ApplicationFiled: March 7, 2013Publication date: September 12, 2013Applicants: Director-Gen. of Nat. Inst. of Infectious Diseases, GC CORPORATIONInventors: Ryoma NAKAO, Hidenobu SENPUKU, Makoto ONISHI, Kazuto TAKAYAMA, Hiroki NAITO, Tetsuo SAKUMA
-
Patent number: 8530152Abstract: The present invention discloses methods of reducing non-specific interactions of interfering species present in a sample in metallic nanoparticle-based assays, thereby increasing the sensitivity of these assays. In particular, the methods entail neutralizing the chemical reactivity of functional groups present in interfering species by addition of a neutralizing agent, such as an alkylating agent or heavy metal ion. The methods are especially useful in assays for the detection of analytes in biological samples. Reagent kits and assay mixtures for the practice of the described methods are also disclosed.Type: GrantFiled: July 9, 2009Date of Patent: September 10, 2013Assignee: Abaxis, Inc.Inventors: Rajesh K. Mehra, Vincent Chiang, Kenneth Aron
-
Publication number: 20130230462Abstract: Disclosed are methods of identifying an individual having a predisposition to the development of a cardiovascular disease, and administering a suitable prophylactic agent to the identified individual to prevent disease. Methods of screening and identifying agents that inhibit bacterial collagen binding protein (CBP)-mediated cell invasion are also disclosed.Type: ApplicationFiled: August 22, 2011Publication date: September 5, 2013Applicants: UNIVERSITY OF FLORIDA, UNIVERSITY OF ROCHESTERInventors: Jacqueline Abranches, José A. Lemos, Robert A. Burne
-
Publication number: 20130217037Abstract: The present invention relates to nanoparticles the surface of which is modified by deposition of proteins. The invention further relates to a method for producing said nanoparticles and to their use in biological research and in the biomedical field (for example labelling and diagnosis).Type: ApplicationFiled: February 11, 2013Publication date: August 22, 2013Inventors: Alain Brisson, Stephane Mornet
-
Publication number: 20130216997Abstract: Disclosed are methods and systems for the isolation and detection of microbes from a sample. The use of binding agents for isolation of a microbe of interest from a sample are described. In certain embodiments, the methods use ribosome-based and/or bacteriophage-based amplification of the signal in detection of bacteria and other microorganisms. For example, embodiments of the present invention can achieve total amplification of at least 10,000 from a single infected cell.Type: ApplicationFiled: February 21, 2013Publication date: August 22, 2013Applicant: LABORATORY CORPORATION OF AMERICA HOLDINGSInventor: Laboratory Corporation of America Holdings
-
Publication number: 20130209988Abstract: Methods and systems for selectively capturing analytes, such as cells, e.g., circulating tumor cells (CTCs), from fluid samples are disclosed. The methods include contacting the sample with an analyte binding moiety that selectively binds to the analytes; optionally separating first components of the sample including a majority of the analytes bound to the binding moieties from second components of the sample using size-based separation, e.g.Type: ApplicationFiled: November 23, 2010Publication date: August 15, 2013Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Thomas A. Barber, Ajay Shah, John Walsh, Mehmet Toner, Ravi Kapur, Shannon L. Stott
-
Patent number: 8507211Abstract: A method of diagnosing in a host infection by or exposure to a mycobacterium which expresses ESAT-6 comprising (i) contacting a population of T cells from the host with one or more peptides or analogues selected from the peptides represented by SEQ ID NO:1 to 11 and analogues thereof which can bind a T cell receptor which recognises any of the said peptides, and (ii) determining whether the T cells of said T cell population recognise the peptide(s) and/or analogue(s). The method may performed in vivo. Peptides and a kit which enable the method to be carried out are provided.Type: GrantFiled: June 6, 2012Date of Patent: August 13, 2013Assignee: Isis Innovation LimtiedInventors: Ajit Lalvani, Ansar Pathan
-
Patent number: 8507237Abstract: The invention concerns a device and a method for concentrating pathogenic germs potentiaily present in blood products or derivatives and for detecting said germs comprising the following steps: (a) subjecting a sample of said blood product to a blood cell aggregating treatment, (b) eliminating the aggregates formed at step (a) by passing the treated sample over a first filter allowing through the contaminating germs but not the cell aggregates, (c) selectively lyzing the residual cells of the filtrate obtained at step (b), (d) recuperating the contaminating germs by passing the lysate of step (c) over a second filter to detect the contaminating germs possibly trapped.Type: GrantFiled: March 8, 2004Date of Patent: August 13, 2013Assignee: GeneOhm Sciences, Inc.Inventors: Jean-Pierre Hermet, Isabelle Besson-Faure, Sébastien Ribault, Yann Godfrin, Anne Monnot des Angles
-
Patent number: 8501182Abstract: The present disclosure relates to monoclonal antibodies that bind poly-?-D-glutamic acid (?DPGA), which is present on the surface of Bacillus anthracis. The disclosure also provides chimeric forms of the monoclonal antibodies, humanized forms of the monoclonal antibodies, and fragments thereof, as well as nucleic acids encoding the antibodies and fragments thereof. Pharmaceutical compositions including such antibodies are also disclosed herein. The disclosure further provides prophylactic, therapeutic, and diagnostic methods of using the disclosed antibodies.Type: GrantFiled: November 19, 2009Date of Patent: August 6, 2013Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human ServicesInventors: Zhaochun Chen, Robert H. Purcell, Rachel Schneerson, Joanna Kubler-Kielb, Lily Z. Dai
-
Patent number: 8497081Abstract: Methods for detecting BoNT/A activity in a sample, methods for screening molecules able to compete with BoNT/A receptor binding, methods for reducing BoNT/A activity in a human and methods of marketing a neurotoxin capable of selectively binding to a FGFR2, a FGFR3, a SV2, or any combination thereof, to a governmental or regional regulatory authority.Type: GrantFiled: May 20, 2009Date of Patent: July 30, 2013Assignee: Allergan, Inc.Inventors: Ester Fernandez-Salas, Birgitte P. S. Jacky, Patton E. Garay, Kei Roger Aoki
-
Patent number: 8492098Abstract: Methods are described for detecting reaction components with affect a reaction. Biomolecules such as enzymes can be addressed at the single molecule level in order to discover function, detect binding partners or inhibitors, and/or measure rate constants.Type: GrantFiled: February 16, 2007Date of Patent: July 23, 2013Assignee: The Trustees of Tufts CollegeInventors: David R. Walt, David M. Rissin, Hans-Heiner Gorris
-
Patent number: 8492103Abstract: The present invention provides an isolated Ehrlichia peptide and therapeutic and diagnostic uses therefor.Type: GrantFiled: January 31, 2012Date of Patent: July 23, 2013Assignee: The Board of Regents of the University of Texas SystemInventors: Sunil Thomas, David H. Walker
-
Patent number: 8486721Abstract: Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample with magnetic sacrificial beads opsonized to leukocytes, binding leukocytes in the sample to the magnetic sacrificial beads, and magnetically retaining the beads out of contact from an immunosensor.Type: GrantFiled: July 27, 2012Date of Patent: July 16, 2013Assignee: Abbott Point of Care Inc.Inventors: John Lewis Emerson Campbell, Graham Davis